The role of biomarkers in glioblastoma diagnosis: Will tissue diagnosis still be needed?

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Molecular abnormalities in gliomas that carry significant diagnostic, therapeutic, and prognostic implications are increasingly recognized including IDH mutation, 1p/19q chromosome co-deletion, and MGMT promoter methylation. These and other biomarkers can also be increasingly detected by imaging or blood and body fluid analysis. This raises the question of whether tissue diagnosis is still needed in this molecular era. We will review current knowledge of biomarkers in gliomas, non-invasive methods for assessing these biomarkers, and the pros and cons of biomarker assessment vs. tissue diagnosis.

Original languageEnglish (US)
Title of host publicationGlioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome
PublisherNova Science Publishers, Inc.
Pages123-134
Number of pages12
ISBN (Print)9781634832892, 9781634832731
StatePublished - Jul 1 2015

Fingerprint

Glioblastoma
Biomarkers
Glioma
Chromosome Deletion
Body Fluids
Methylation
Mutation
Therapeutics

Keywords

  • 1p/19q
  • Biomarker
  • Biopsy
  • Glioblastoma
  • IDH
  • MGMT
  • Spectroscopy
  • Texture

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Parney, I. F., Malucelli, A., Gustafson, M., & Dietz, A. B. (2015). The role of biomarkers in glioblastoma diagnosis: Will tissue diagnosis still be needed? In Glioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome (pp. 123-134). Nova Science Publishers, Inc..

The role of biomarkers in glioblastoma diagnosis : Will tissue diagnosis still be needed? / Parney, Ian F; Malucelli, Alberto; Gustafson, Michael; Dietz, Allan B.

Glioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome. Nova Science Publishers, Inc., 2015. p. 123-134.

Research output: Chapter in Book/Report/Conference proceedingChapter

Parney, IF, Malucelli, A, Gustafson, M & Dietz, AB 2015, The role of biomarkers in glioblastoma diagnosis: Will tissue diagnosis still be needed? in Glioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome. Nova Science Publishers, Inc., pp. 123-134.
Parney IF, Malucelli A, Gustafson M, Dietz AB. The role of biomarkers in glioblastoma diagnosis: Will tissue diagnosis still be needed? In Glioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome. Nova Science Publishers, Inc. 2015. p. 123-134
Parney, Ian F ; Malucelli, Alberto ; Gustafson, Michael ; Dietz, Allan B. / The role of biomarkers in glioblastoma diagnosis : Will tissue diagnosis still be needed?. Glioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome. Nova Science Publishers, Inc., 2015. pp. 123-134
@inbook{8ffb8527e9874fbc878cf2f38c47961f,
title = "The role of biomarkers in glioblastoma diagnosis: Will tissue diagnosis still be needed?",
abstract = "Molecular abnormalities in gliomas that carry significant diagnostic, therapeutic, and prognostic implications are increasingly recognized including IDH mutation, 1p/19q chromosome co-deletion, and MGMT promoter methylation. These and other biomarkers can also be increasingly detected by imaging or blood and body fluid analysis. This raises the question of whether tissue diagnosis is still needed in this molecular era. We will review current knowledge of biomarkers in gliomas, non-invasive methods for assessing these biomarkers, and the pros and cons of biomarker assessment vs. tissue diagnosis.",
keywords = "1p/19q, Biomarker, Biopsy, Glioblastoma, IDH, MGMT, Spectroscopy, Texture",
author = "Parney, {Ian F} and Alberto Malucelli and Michael Gustafson and Dietz, {Allan B}",
year = "2015",
month = "7",
day = "1",
language = "English (US)",
isbn = "9781634832892",
pages = "123--134",
booktitle = "Glioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - The role of biomarkers in glioblastoma diagnosis

T2 - Will tissue diagnosis still be needed?

AU - Parney, Ian F

AU - Malucelli, Alberto

AU - Gustafson, Michael

AU - Dietz, Allan B

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Molecular abnormalities in gliomas that carry significant diagnostic, therapeutic, and prognostic implications are increasingly recognized including IDH mutation, 1p/19q chromosome co-deletion, and MGMT promoter methylation. These and other biomarkers can also be increasingly detected by imaging or blood and body fluid analysis. This raises the question of whether tissue diagnosis is still needed in this molecular era. We will review current knowledge of biomarkers in gliomas, non-invasive methods for assessing these biomarkers, and the pros and cons of biomarker assessment vs. tissue diagnosis.

AB - Molecular abnormalities in gliomas that carry significant diagnostic, therapeutic, and prognostic implications are increasingly recognized including IDH mutation, 1p/19q chromosome co-deletion, and MGMT promoter methylation. These and other biomarkers can also be increasingly detected by imaging or blood and body fluid analysis. This raises the question of whether tissue diagnosis is still needed in this molecular era. We will review current knowledge of biomarkers in gliomas, non-invasive methods for assessing these biomarkers, and the pros and cons of biomarker assessment vs. tissue diagnosis.

KW - 1p/19q

KW - Biomarker

KW - Biopsy

KW - Glioblastoma

KW - IDH

KW - MGMT

KW - Spectroscopy

KW - Texture

UR - http://www.scopus.com/inward/record.url?scp=84957950529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957950529&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84957950529

SN - 9781634832892

SN - 9781634832731

SP - 123

EP - 134

BT - Glioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome

PB - Nova Science Publishers, Inc.

ER -